Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Bavarian Nordic A/S    BAVA   DK0015998017

BAVARIAN NORDIC A/S (BAVA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
04/18/2018 04/19/2018 04/20/2018 04/23/2018 04/24/2018 Date
179.15(c) 175.4(c) 169.7(c) 166.25(c) 164.5 Last
354 144 743 509 531 502 401 563 486 120 Volume
+5.85% -2.09% -3.25% -2.03% -1.05% Change
More quotes
Financials (DKK)
Sales 2018 565 M
EBIT 2018 -320 M
Net income 2018 -236 M
Finance 2018 1 801 M
Yield 2018 -
Sales 2019 958 M
EBIT 2019 5,58 M
Net income 2019 39,1 M
Finance 2019 1 869 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 39,12
EV / Sales2018 6,55x
EV / Sales2019 3,79x
Capitalization 5 498 M
More Financials
Company
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate... 
Sector
Pharmaceuticals
Calendar
05/24Earnings Release
More about the company
Surperformance© ratings of Bavarian Nordic A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on BAVARIAN NORDIC A/S
04/23BAVARIAN NORDIC A/S : - Report on the Results of the Annual General Meeting, hel..
AQ
04/19BAVARIAN NORDIC A/S : BioPorto appoints Ole Larsen as CFO
AQ
04/17BAVARIAN NORDIC A/S : Report on the Results of the Annual General Meeting, held ..
PU
04/17BAVARIAN NORDIC A/S : A/S - Report on the Results of the Annual General Meeting,..
GL
03/27BAVARIAN NORDIC A/S : to Present at Needham & Company's 17th Annual Healthcare C..
GL
03/26BAVARIAN NORDIC A/S : A/S - Notice Convening Ordinary General Meeting
GL
03/21BAVARIAN NORDIC A/S : Announces Partnership with U.S. Department of Defense to C..
AQ
03/17BAVARIAN NORDIC A/S : Announces Partnership with U.S. Department of Defense to C..
AQ
03/16BAVARIAN NORDIC A/S : Announces Partnership with U.S. Department of Defense to C..
GL
03/15BRISTOL MYERS SQUIBB : Bavarian Nordic Announces Annual Report 2017
AQ
More news
Sector news : Pharmaceuticals - NEC
08:56aASTRAZENECA : Negative Results From Phase 3 Trial of Imfinzi and Tremelimumab
DJ
08:37aASTRAZENECA : to raise stake in Circassia to up to 19.9 percent
RE
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
04/23SUSAN KILSBY : Holding(s) In Company
DJ
04/23INVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
03/27Bavarian Nordic A/S: Bavarian Nordic to Present at Needham & Company's 17.. 
03/27Bavarian Nordic A/S : to Present at Needham & Company's 17th Annual Healt.. 
03/20Argument here is similar to Bavarian Nordic, where we correctly predicted Pha..
3
03/16Bavarian Nordic Announces Partnership with U.S. Department of Defense to Comb.. 
03/16Bavarian Nordic inks deal with U.S. DoD for equine encephalitis virus vaccine.. 
More tweets
Qtime:44
News from SeekingAlpha
03/13Bavarian Nordic A/S 2017 Q4 - Results - Earnings Call Slides 
03/12Bavarian Nordic's (BVNKF) CEO Paul Chaplin on Q4 2017 Results - Earnings Call.. 
03/12Bavarian Nordic A/S reports FY results 
02/283 THINGS IN BIOTECH YOU SHOULD LEARN : February 27, 2018 
2017Bavarian Nordic's (BVNKF) CEO Paul Chaplin on Q3 2017 Results - Earnings Call.. 
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | BAVA | DK0015998017 | 4-Traders
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 295  DKK
Spread / Average Target 78%
EPS Revisions
Managers
NameTitle
Paul Chaplin President & Chief Executive Officer
Gerardus Wilhelmus van Odijk Chairman
Henrik Birk Chief Operating Officer & Executive Vice President
Ole Larsen Chief Financial Officer & Executive Vice President
Christopher R. Heery Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAVARIAN NORDIC A/S-24.34%902
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY7.07%158 571